Ajinomoto Bio-Pharma Services and Revance Therapeutics have announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.
Revance Therapeutics says developing a Botox biosimilar is “challenging, but not impossible” in reply to AbbVie’s dismissal of the prospect of a copy of the blockbuster coming to market.
Allergan will expand its existing facilities in Ireland through an investment of €65m to produce new product formats for existing and investigational products.